Statin Therapy to Reduce Progression in Platinum Sensitive Ovarian Cancer

What is the Purpose of this Study?

The purpose of this study is to evaluate the use of an investigational drug called simvastatin in women with platinum-sensitive ovarian cancer who are planning to begin treatment with carboplatin and liposomal doxorubicin. Researchers aim to determine the feasibility and effectiveness of a simvastatin intervention during chemotherapy treatment (whether it will help reduce disease progression). Participants will receive simvastatin during their chemotherapy treatment for approximately 6 months, and medical records will be reviewed.


Eligibility

  • * Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment.
  • * No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin.
Show more

Where can I participate?

Cedars-Sinai Cancer at SOCC

More about this Clinical Trial

What is the full name of this clinical trial?

IIT2020-03-Rimel-STOV: Statin Therapy to Reduce Progression in Women with Platinum Sensitive Ovarian Cancer

Study Details
Disease Type/Condition

Ovary

Principal Investigator

Rimel, Bobbie Jo

Co-Investigators

Andrew Li, Kenneth Kim, Kristin Taylor, Marc Goodman, Margaret Liang

Age Group

Adult

Phase

I

IRB Number

STUDY00000817

ClinicalTrials.gov ID

NCT04457089

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Ovary

Principal Investigator

Rimel, Bobbie Jo

Age Group

Adult

Phase

I

IRB Number

IIT2020-03-RIMEL-STOV

ClinicalTrials.gov ID

NCT04457089

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org